Regenerative life sciences company Nanovis said today it won a grant from the National Institute of Health’s National Institute on Aging to fund pre-clinical studies of its FortiCore interbody fusion device.
Carmel, Ind.-based Nanovis said the grant is the 8th that the company has received from the NIH and other research organizations.
“The surface structure of medical devices plays a critical role in how the body heals around an implant. Mimicking natural surfaces at the nano scale, about the size of a protein, to encourage natural regenerative processes may improve results for patients challenged to quickly heal on their own. Nanovis’ science-focused approach to developing unique implant technologies shows significant potential to enhance performance. This research will evaluate the differentiated capabilities and unique potential of these advanced technologies,” co-investigator Dr. Rick Guyer said in prepared remarks.
The company’s FortiCore interbody fusion device will be studied along with its preclinical nanosurfaced FortiFix pedical screws to examine the potential impact on improving aspects of recovery after spinal fusion procedures.
“Gaining the attention and support of the NIH for Nanovis’ technology platforms and research is gratifying. Our deeply porous FortiCore interbody fusion device are increasingly being adopted by leading surgeons and hospital networks driving accelerated company growth. As we progress forward, we continue to invest in the fundamental science at the core of our uniquely differentiated technologies. Grants from the NIH help us continue to discover potential applications to improve the future of healthcare,” CEO Matt Hedrick said in a press release.
